[go: up one dir, main page]

SV2002000035A - Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11121/rm/ta - Google Patents

Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11121/rm/ta

Info

Publication number
SV2002000035A
SV2002000035A SV2000000035A SV2000000035A SV2002000035A SV 2002000035 A SV2002000035 A SV 2002000035A SV 2000000035 A SV2000000035 A SV 2000000035A SV 2000000035 A SV2000000035 A SV 2000000035A SV 2002000035 A SV2002000035 A SV 2002000035A
Authority
SV
El Salvador
Prior art keywords
dihydroxyl
hmg
open acid
reductase
ref
Prior art date
Application number
SV2000000035A
Other languages
English (en)
Inventor
Edward J J Grabowski
Richard D Tillyer
Paul J Reider
Feng Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of SV2002000035A publication Critical patent/SV2002000035A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL PRESENTE INVENTO OFRECE METODOS Y COMPOSICIONES FARMACEUTICAS PARA LA INHIBICION DE REDUCTASA HMG-CoA, ASI COMO EL TRATAMIENTO Y/O REDUCCION DEL RIESGO DE ENFERMEDADES Y CONDICIONES QUE AFECTEN LA INHIBICION DE REDUCTASA HMG-CoA, QUE COMPRENDE LA ADMINISTRACION ORAL DE UNA CANTIDAD EFECTIVA TERAPEUTICAMENTE DE UNA FORMA CRISTALINA HIDRATADA DE LA SAL DE CALCIO DE SIMVASTATINA DE ACIDO ABIERTO DE DIHIDROXILO A UN PACIENTE QUE NECESITE DICHO TRATAMIENTO. TAMBIEN SE OFRECEN LOS METODOS PARA FABRICAR LA SAL DE CALCIO DE SIMVASTATINA DE ACIDO ABIERTO DE DIHIDROXILO.
SV2000000035A 1999-03-08 2000-03-08 Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11121/rm/ta SV2002000035A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12324799P 1999-03-08 1999-03-08
US26474599A 1999-03-09 1999-03-09
PCT/US2000/002627 WO2000053566A1 (en) 1999-03-08 2000-02-02 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt

Publications (1)

Publication Number Publication Date
SV2002000035A true SV2002000035A (es) 2002-01-15

Family

ID=26821372

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000035A SV2002000035A (es) 1999-03-08 2000-03-08 Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11121/rm/ta

Country Status (16)

Country Link
EP (2) EP1163203A1 (es)
JP (2) JP2002539108A (es)
AR (1) AR022857A1 (es)
AT (1) ATE240934T1 (es)
AU (1) AU764048B2 (es)
CA (1) CA2365869A1 (es)
CO (1) CO5150184A1 (es)
DE (1) DE60002769T9 (es)
DK (1) DK1036783T3 (es)
ES (1) ES2198253T3 (es)
HN (1) HN2000000031A (es)
PE (1) PE20001469A1 (es)
PT (1) PT1036783E (es)
SI (1) SI1036783T1 (es)
SV (1) SV2002000035A (es)
WO (1) WO2000053566A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6558659B2 (en) 2000-04-10 2003-05-06 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
WO2002020457A1 (en) * 2000-09-06 2002-03-14 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
EP1322306A2 (en) * 2000-09-19 2003-07-02 NovImmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
CZ2004943A3 (cs) 2002-03-18 2005-02-16 Biocon Limited Amorfní HMG-CoA inhibitory obsahující reduktázu s požadovanou velikostí částic
US20030195167A1 (en) * 2002-04-15 2003-10-16 Kowa Co., Ltd. PTX3-gene expression inhibitor
DK1515717T3 (da) * 2002-06-13 2009-02-09 Novartis Ag Calciumsalte af indolafledte statiner
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
KR20050098313A (ko) 2003-02-11 2005-10-11 플러스 케미칼스 비.브이. 제어된 범위의 심바스타틴 이량체 함량을 갖는심바스타틴의 제조 방법
EP1790635A3 (en) 2003-06-18 2007-06-13 Teva Pharmaceutical Industries, Inc. Processes for preparing amorphous fluvastatin sodium
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
US7368581B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
JPWO2006115130A1 (ja) * 2005-04-19 2008-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ビス［（２ｓ）−３−［３−［（２ｓ）−３−（４−クロロ−２−シアノフェノキシ）−２−フルオロプロポキシ］フェニル］−２−イソプロポキシプロピオン酸］カルシウム及びその中間体
US7816405B2 (en) 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
KR20130100297A (ko) * 2010-08-27 2013-09-10 어드밴스드 테크놀러지 머티리얼즈, 인코포레이티드 건조 동안의 높은 종횡비 구조물의 붕괴 방지 방법
WO2014036548A1 (en) * 2012-08-31 2014-03-06 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Macromolecular prodrugs for hard tissue and methods of use thereof
GB201704687D0 (en) 2017-03-24 2017-05-10 Wockhardt Uk Ltd Pharmaceutical composition of simvastatin or salt thereof
CN113686991A (zh) * 2021-08-31 2021-11-23 南京西默思博检测技术有限公司 测定人血浆中辛伐他汀、β-羟酸辛伐他汀的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)

Also Published As

Publication number Publication date
EP1163203A1 (en) 2001-12-19
EP1036783A1 (en) 2000-09-20
SI1036783T1 (en) 2003-08-31
ES2198253T3 (es) 2004-02-01
EP1036783B1 (en) 2003-05-21
DE60002769D1 (de) 2003-06-26
WO2000053566A1 (en) 2000-09-14
AU2637000A (en) 2000-09-28
AR022857A1 (es) 2002-09-04
AU764048B2 (en) 2003-08-07
DK1036783T3 (da) 2003-06-23
ATE240934T1 (de) 2003-06-15
PT1036783E (pt) 2003-08-29
JP2002539108A (ja) 2002-11-19
CO5150184A1 (es) 2002-04-29
DE60002769T9 (de) 2004-11-04
PE20001469A1 (es) 2000-12-18
HN2000000031A (es) 2001-09-25
DE60002769T2 (de) 2004-03-18
JP2000281626A (ja) 2000-10-10
CA2365869A1 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
SV2002000035A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11121/rm/ta
SV2002000036A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma
GT200500060A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
GEP20257811B (en) Pharmaceutical combinations of sos1 inhibitors
CY1108105T1 (el) Ιβανδρονικο οξυ για την θεραπευτικη αντιμετωπιση και την προληψη της οστεoπορωσης
UY26782A1 (es) Derivados del benzotiazol
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
UY26839A1 (es) Productos de derivados de la 4 - fenil - piridina
ATE361300T1 (de) Derivate von heteroarylnitrilverbindungen
ATE469674T1 (de) 5-aminolävulinsäure-derivate zur behandlung von akne
BR0309259A (pt) Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
MX2024014117A (es) Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas
ES2168581T3 (es) Derivados de indazol sustituidos.
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
EP1192949A4 (en) PREVENTIVE OR THERAPEUTIC DRUGS FOR TREATING FIBROSIS AND CONTAINING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
PT1206444E (pt) Compostos que inibem a actividade da triptase
AR131735A1 (es) Agentes terapéuticos